EBS
Emergent BioSolutions Inc.
NYSE · Healthcare · Drug Manufacturers - Specialty & Generic · US
$6.38
−11.14%Price chart
Sep 17Sep 22Sep 25Sep 30Oct 5Oct 8Oct 13Oct 16
Key dataOct 16, 2026
Open$6.61
From 52W high−54.10%
Volume2.24M
Market cap$327.12M
P/E (TTM)—
P/S (TTM)0.4x
Div yield—
Key dataOct 16, 2026
Open
$6.61
From 52W high
−54.10%
Volume
2.24M
Market cap
$327.12M
ValuationView details →
P/E (Fwd)
13.8x
EV/EBITDA
−1098.9x
P/E (TTM)
—
RSI (14)
45.9
MomentumView details →
1D Return
−11.14%
YTD Return
−47.86%
SummaryUpdated Jun 1, 2026
Emergent BioSolutions Inc. (NYSE:EBS) is a specialized life sciences company founded in 1998 and headquartered in Gaithersburg, Maryland. The company went public in 2006 and has evolved into a leading provider of medical countermeasures and emergency response solutions for public health threats. Emergent focuses on addressing chemical, biological, radiological, nuclear, and explosive threats, as well as emerging infectious diseases and opioid overdose emergencies. The company has undergone significant strategic transformation in recent years, streamlining operations and focusing on its core competencies in biodefense and overdose prevention.
Similar companies
Latest newsMore news →
Emergent BioSolutions said Richard S. Lindahl will retire as executive vice president and chief financial officer effective December 31, 2026, and become a senior executive advisor on January 1, 2027; Frank Vargo will become interim chief financial officer on January 1, 2027.9h agoEmergent Biosolutions (EBS) shares rose 14.4% in the previous trading session on higher-than-average trading volume.10d ago